Stuttgart
31.07.26 | 21:55
1,834 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,818 | 1,970 | 02.08. | |
| 1,832 | 1,886 | 31.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.07. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 373 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 06.07. | ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA | 812 | Business Wire | Regulatory News:
Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account... ► Artikel lesen | |
| 30.06. | ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis | 383 | Business Wire | All resolutions submitted for a vote at today's Combined General Meeting were approved Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide... ► Artikel lesen | |
| 18.06. | ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M | 621 | Business Wire | Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share Drawdown of the First Tranche... ► Artikel lesen | |
| 09.06. | ABIONYX Pharma: Combined Annual Shareholders' Meeting on June 30, 2026: Availability of preparatory documents and procedures for participation and voting | 398 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary... ► Artikel lesen | |
| 02.06. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 389 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 29.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026 | 408 | Xetra Newsboard | Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded... ► Artikel lesen | |
| ABIONYX PHARMA Aktie jetzt für 0€ handeln | |||||
| 28.05. | ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026 | 536 | Business Wire | Consolidated revenue of €0.8 million as of the end of March 2026 and €2.6 million secured for the year Cash position of €2.8 million as of March 31, 2026, stable compared to December 31... ► Artikel lesen | |
| 27.05. | ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M | 647 | Business Wire | Size of the Fully Guaranteed Capital Increase with subscription rights: EUR 32.7m Subscription ratio: 1 new share for every 5 existing shares Subscription price: 2.65 euro per new... ► Artikel lesen | |
| 07.05. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 463 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 09.04. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 497 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 27.03. | ABIONYX Pharma Achieves Major Milestone in apoA-I Biomanufacturing with Breakthrough in Synthetic Sphingomyelin Production | 472 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an... ► Artikel lesen | |
| 17.03. | ABIONYX Pharma: Availability of the Universal Registration Document for the year 2025 | 407 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an... ► Artikel lesen | |
| 03.03. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 425 | Business Wire | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 26.02. | ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2025 | 650 | Business Wire | Consolidated revenue of €4.1 million at the end of December 2025 Cash position of €3.5 million as of December 31, 2025 Cash runway through year-end 2026 excluding France 2030 non-dilutive... ► Artikel lesen | |
| 04.02. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 472 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 28.01. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 449 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 23.01. | ABIONYX Pharma Announces Its Financial Calendar for the Year 2026 | 526 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary... ► Artikel lesen | |
| 07.01. | ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA | 526 | Business Wire | Regulatory News:
Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on... ► Artikel lesen | |
| 17.12.25 | ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m | 509 | Business Wire | Capital increase of approximately 1.8 million euros Subscription price: 3.10 euros Extension of financial visibility until the end of 2026
Regulatory News:
ABIONYX Pharma, (FR0012616852... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,05 | -1,37 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| EVOTEC | 3,410 | -1,22 % | Keine Ende der Rallye in Sicht: Diese Biotechnologie-Aktie bietet für ihr Geld so viel wie kaum eine zweite! | © Foto: ZUMAPRESS.com | La Nacion - picture allianceTrotz eines enorm starken Wachstums und einer günstigen Unternehmensbewertung ist Halozyme noch immer ein Nischenwert. Das dürfte nicht mehr lange... ► Artikel lesen | |
| BB BIOTECH | 55,20 | +0,18 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,007 | +2,78 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| MODERNA | 48,575 | +2,23 % | Ihre wichtigsten Termine: Spannende Zahlen von: Sony, Moderna, AbbVie, Eaton, ExxonMobil, Linde und Puma! | © Foto: picture alliance / CFOTO | CFOTOGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| VALNEVA | 2,167 | +0,37 % | Valnevas Strategie mit dem VLA15-Impfstoff: Ein Gamechanger in der Biotechnologie? | ||
| AMGEN | 334,20 | +0,03 % | EQS-News: Amgen: Positive Stellungnahme des CHMP unterstützt breitere Anwendung von Amgens Repatha vor erstem Herzinfarkt oder Schlaganfall | EQS-News: Amgen
/ Schlagwort(e): Sonstiges
POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL... ► Artikel lesen | |
| EPIGENOMICS | 0,940 | -0,53 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,320 | -0,47 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| STRYKER | 282,50 | 0,00 % | Stryker Corp. Bottom Line Rises In Q2 | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed a profit for its second quarter that Increases, from the same period last yearThe company's bottom line came in at $1.276 billion, or $3.30... ► Artikel lesen | |
| BIOGEN | 176,60 | +0,32 % | Ihre wichtigsten Termine: Heute im Fokus: Meta, Microsoft, Qualcomm, Biogen, Airbus, Porsche und L' Oréal | © Foto: Andrej Sokolow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:30... ► Artikel lesen | |
| BIOFRONTERA | 2,510 | -0,40 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,510 | +1,21 % | Heidelberg Pharma: Der Finanzpuffer öffnet ein Zeitfenster | ||
| CRISPR THERAPEUTICS | 41,580 | -0,11 % | Morningstar, Inc.: Morningstar Completes Rebrand of CRSP Market Indexes to Morningstar Market Indexes | Indexes underpinning more than $3 trillion in investor assets move under the Morningstar brand, expanding visibility and supporting future growth
Morningstar, Inc. (NASDAQ: MORN), a leading provider... ► Artikel lesen |
ABIONYX PHARMA SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,834 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABIONYX PHARMA SA finden Sie auf Wallstreet Online.